Jump to content

forrestgump

Member
  • Posts

    2916
  • Joined

  • Last visited

Everything posted by forrestgump

  1. I noticed late last week that this one was showing a bit of interest, SP wise. Solid buying today, Huge volume and sellers retreating. +27% as I post. I have no idea why.
  2. The trial of the anti cancer vaccine RGSH4K is getting some press. http://www.abc.net.au/pm/content/2015/s4242090.htm
  3. Finally, some encouraging news. http://www.asx.com.au/asx/statistics/displ...;idsId=01606450 01606450.pdf
  4. Patent granted for stem cell based acne treatment. Plans well progressed to commercialise quickly. IMO, this could be a nice little earner if managed and marketed correctly. http://www.aspectfinancial.com.au/docserve...WxheWVkLmpzcA==
  5. Regeneus obtains worldwide exclusive human rights to the Kvax personalised cancer treatment. They already have the Veterinary rights and are reporting good results with it. http://www.asx.com.au/asx/statistics/displ...;idsId=01532130
  6. Proactive Investors on Regeneus.
  7. Regeneus enters into US marketing trial agreement for novel canine cancer vaccine Sydney, Australia – 30 June 2014
  8. Thanks for that doc-p. Most encouraging. Purely coincidentally, yesterday I was chatting to a friend of a friend and he was telling me that a friend of his is about to have the Regeneus stem cell treatment for her knee. It seems that the process is progressively gaining some traction. However, as we always knew, these biotech companies do have a long gestation and we need to continue to be patient as we await more good news. We picked up a parcel of 50,000 shares today.
  9. Things starting to move along now. The following is excellent news. http://regeneus.com.au/news/news-release-r...onors-first-man
  10. http://www.proactiveinvestors.com.au/compa...ults-53905.html
  11. http://regeneus.com.au/news/news-release-o...nt-improvements
  12. http://www.investing.com/analysis/regeneus...r-growth-207306
  13. This is still a speculative stock. One of the major traits of a speculative stock is that it is nigh on impossible to attach any meaningful value to the stock. It is worth anything between zero and "eleventy billion dollars". The true current value will only really be known some time down the road (years, probably). In the meantime, the pricing is on a "relative basis". That means that when any event happens the price reacts with "it is worth more/less than yesterday" (even though yesterday's price was equally meaningless). Of course none of that really answers your question. The best answer that I can give you is that the stock is doing exactly what speculative stocks do. That is, the price goes up when they have a good announcement and then drifts until the next announcement. Of course many other factors determine the size of these moves also. For example, if the stock is quite tightly held by investors that believe in the future of the company then the down drifts tend to be more muted. Given the fact that RGS has held up quite strongly since the last announcement then you might assume that that is the case. Watching the volumes that go through can help you to come to grips with that. It is also quite possible for a stock to gyrate wildly on quite low volumes. What will RGS do next? Frankly, I've been playing this game far too long to believe that I can predict what will happen in the short term. Read the reports from the AGM. You will see that the Company has plenty of good news that it will announce over the coming months and years. For what it's worth (probably worth about what I am charging you for it), I am still holding all of the shares that I have from float. Having attended the AGM, I doubt that I will be selling any of them any time soon. I think that this Company has products, management and strategies in place that give it a better than average chance of becoming a success. That is about the best that you can hope for in a speculative investment. I'm bloody careful with my money - it is a rare "speccy" that sees any of it.
  14. MMS have just announced that their Novated Lease business is now back up to 95% of the pre "incident" levels.
  15. Google Earth is not live. You are seeing pictures that may have been taking months (or even years) earlier.
  16. It seems that our little Regeneus is starting to pop up on radars. The following article is a worthwhile read - particularly for anybody that is not yet up to speed on exactly what it is that Regeneus does. Proactive Investors Add the Kvax cancer vaccine to all of that and Regeneus has great potential to reward.
  17. Just a reminder. the Annual General Meeting of Members of Regeneus Ltd (the Company) will be held at the offices of DibbsBarker Lawyers, Level 8, 123 Pitt Street, Sydney NSW on Wednesday, 27 November 2013 at 1.00pm (Sydney time).
  18. Just a quick post to note that the Autologous Cancer Vaccine has now been given a name - Kvax My understanding is that Regeneus have the worldwide rights to the use of Kvax in animals and they have "first right of refusal" on the same for humans. Let's hope that they formally take up that option - it would certainly add to the value of the Company.
  19. That really is a good summary. Thanks. This investment is actually showing promise of turning out better that even I had thought it might (and I'm not just referring to the share price). I entered this investment on the stem cell technology, however the nice surprise of the potential cancer vaccine has put whipped cream on this pie. In fact, the Cancer vaccine may, in time, become the pie. Whilst we all know that trials in rats don't always translate well into other animals (eg humans), those rat trial results are truly phenomenal. A 40% total cure rate plus 100% resistance to future re-challenge is quite stunning. It will be most interesting to watch the unfolding of the results in dogs in the trials in the USA. As with most biotechs, there is, of course, a long way to go but every journey starts with the first step. The Company has now made some solid and confident first steps in both the stem cell and cancer vaccine spaces.
  20. Trading commencing today. I suspect that a lot of people will be watching this one as it is the first biotech float in Australia for some time.
  21. I am led to believe that the amount raised was within the anticipated limits so there should not be any scaling down.
  22. This is a recent article from the ABC that talks about the potential cancer treatment developed at the Kolling Institute that is mentioned in the Regeneus prospectus. This has no direct relationship with Regeneus' stem cell work but Regeneus have the worldwide veterinary rights to this treatment and first refusal on the human rights. It's always nice to have a second string to the bow and this one could well be a very strong string. http://www.abc.net.au/news/2013-07-29/canc...-humans/4851234 Canine cancer vaccine could be trialled on humans: researchers By medical reporter Sophie Scott and Jeanavive McGregor Updated Wed 31 Jul 2013, 11:00am AEST Researchers say a new cancer vaccine that appears to be helping dogs could soon be used in human trials. The vaccine, developed by researchers at Sydney's Kolling Institute, has been trialled on almost 30 dogs with advanced melanoma, bone cancer and liver cancer. Early results found the vaccine not only slowed the growth of the original tumour but also helped to prevent more developing. Dr Chris Weir, who developed the vaccine, said the anecdotal results are promising. "I decided to use dogs because they have a high rate of malignancy and because vets use chemotherapy and radiation therapy on dogs with cancer, in much the same way as humans with cancer are treated," he said. "When a vet tells you this dog has 12 months to live and they are kicking on over two years later, you have to hold hope that we can roll this out not only for dogs but also for human patients." The vaccine is made using cells from individual tumours, creating a unique and personalised vaccine for each canine patient. It also contains a bacteria that stimulates the immune system to kill cancer cells. The results of the early trial have not been published in a scientific journal because researchers want to patent the vaccine technology first. Medical oncologist at the Royal North Shore Hospital, Professor Stephen Clarke, hopes that human clinical studies will start in six months to one year."Prior to the last few years, cancer vaccines had been a great hope but hadn't really resulted in any clinical products so we have substantial hope about this," he said. "These guys in the lab have spent quite a lot of time developing the vaccine in the way that it will stimulate the greatest immune reaction, so we have high hopes. "These animals' data are a really good prelude to undertaking clinical studies." Success story for Sally the kelpie Vet student Jenny Millar found out about the study when her kelpie Sally was diagnosed with liver cancer. The kelpie had a tennis ball-sized cancer in her liver. Surgeons were only able to remove 90 per cent of the tumour but Ms Millar wanted to avoid chemotherapy because Sally was nearly 13 years old. "After the surgery we gave her the vaccine and sure enough, two-and-a-half years later, completely defying all expectations, she is still with us," Ms Millar said. She says Sally, now 15, is a happy and healthy old dog with no signs of the cancer reoccurring. "She's the best dog in the world. Nobody was expecting it, we just enjoy every day we have with her," Ms Millar said. Veterinarian Dr Miles Alexander has been using the vaccine since 2011 as an add-on therapy for dogs with terminal cancer. "I have seen no adverse side effects and so far I am encouraged by the patients who have lived well beyond my expectations while maintaining a great quality of life," he says.
×
×
  • Create New...